High-throughput immunoassays underpin efficiency and productivity
Automation is being applied at many levels to power future development of recombinant therapeutic proteins, including screening for the most promising recombinant protein clones. Gregory Keil and co-authors at Merck & Co. have reviewed how this screening can be transformed by combining high-throughput screening methods, analytical techniques and automation to increase capacity, reduce manual operations and risk for error, lower operational costs, and shorten development timelines (see reference).
